ASH 2017 | The DUO trial: providing new hope for CLL patients

Stephan Stilgenbauer

Stephan Stilgenbauer, MD, PhD, of the University of Ulm, Ulm, Germany, talks about the results of the DUO trial, a randomized analysis of ofatumumab versus duvelisib in relapsed refractory CLL patients. Trial was run over a couple of years and met it’s primary endpoint of progression-free survival superiority of duvelisib over ofatumumab. This will likely lead to licensing of duvelisib as a novel treatment option for CLL patients, which will provide new hope beyond chemoimmunotherapy.
Recorded at the American Society of Hematology 2017 Annual Meeting, held in Atlanta, GA.

Share this video